ALNY vs IONS: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ALNY and IONS share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ALNY and IONS exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Alnylam Pharmaceuticals is the company that turned RNA interference, a Nobel-winning biological mechanism for silencing disease-causing genes, into an approved class of medicines. Its commercial portfolio includes Amvuttra (vutrisiran) and Onpattro for transthyretin (TTR) amyloidosis, Givlaari for acute hepatic porphyria, and Oxlumo for a rare kidney disorder, plus royalties on Leqvio, an cholesterol-lowering RNAi drug marketed by partner Novartis. The defining event was the March 2025 FDA approval of Amvuttra for ATTR amyloidosis with cardiomyopathy (ATTR-CM), a far larger patient population than its earlier polyneuropathy indication, based on the HELIOS-B trial showing a 28% reduction in death and cardiac events.

Full ALNY guide

Ionis Pharmaceuticals is a California-based biotechnology company that invented and commercialized antisense technology, a way to design short strands of nucleic acid that silence or modify the RNA behind disease-causing proteins. For decades it operated largely as an R&D and royalty engine, partnering drugs like Spinraza (spinal muscular atrophy, with Biogen) and Wainua (hereditary ATTR polyneuropathy, with AstraZeneca) to larger companies. It now markets around seven medicines and, starting in 2025, launched its first fully owned products, Tryngolza (olezarsen) for familial chylomicronemia syndrome and Dawnzera for hereditary angioedema.

Full IONS guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ALNY drivers: Amvuttra ATTR-CM ramp; Crossing into sustained profitability.
• IONS drivers: Owned commercial launches; Olezarsen label expansion.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Revenue is heavily concentrated in the TTR franchise, so any competitive share loss or reimbursement setback for Amvuttra would hit the whole story. For IONS, ionis still operates at a loss, with 2026 non-GAAP operating loss guidance in the range of roughly $425 million to $475 million, so profitability remains unproven.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ALNY if you believe its drivers more; IONS if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ALNY and IONS guides.

ALNY. Alnylam reached profitability in 2025 after nearly $3 billion in net product revenue, and Q1 2026 delivered about $1.0 billion in net product revenue with roughly $206 million of net income. At a market cap near $42 billion against 2026 revenue guidance of roughly $5 billion, the stock carries a premium multiple that prices in continued rapid growth. It pays no dividend and reinvests cash into its RNAi pipeline.

IONS. Ionis trades as a growth-stage biotech, valued on future product sales rather than current earnings since it remains unprofitable. Revenue is accelerating on owned launches and milestone payments, and management raised full-year 2026 guidance after a strong first quarter. The valuation embeds significant expectations for olezarsen's expansion and the broader pipeline.

Headline figures (approximate, JULY 2026): ALNY shows market cap ~$42B, net product revenue (fy2025) ~$3.0B, net product revenue (ttm) ~$3.5B, 2026 revenue guidance ~$4.9B to $5.3B; IONS shows market cap ~$14B, revenue (2025) ~$944M, q1 2026 revenue ~$246M (up ~87% YoY), 2026 revenue guidance ~$875M-$900M.

ALNY and IONS are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ALNY and IONS exposure against your real portfolio. It is not an investment adviser.